GIULIANI, Nicola
 Distribuzione geografica
Continente #
NA - Nord America 7.449
EU - Europa 6.476
AS - Asia 3.247
Continente sconosciuto - Info sul continente non disponibili 18
AF - Africa 15
OC - Oceania 4
SA - Sud America 2
Totale 17.211
Nazione #
US - Stati Uniti d'America 7.303
CN - Cina 2.572
IE - Irlanda 1.611
SE - Svezia 1.483
FI - Finlandia 1.027
IT - Italia 679
DE - Germania 626
UA - Ucraina 621
TR - Turchia 458
CA - Canada 144
GB - Regno Unito 119
SG - Singapore 93
IN - India 78
AT - Austria 73
RO - Romania 64
BE - Belgio 55
FR - Francia 36
NL - Olanda 20
EU - Europa 18
IR - Iran 17
CZ - Repubblica Ceca 10
ES - Italia 8
HK - Hong Kong 8
BG - Bulgaria 7
IL - Israele 6
NG - Nigeria 5
RU - Federazione Russa 5
AE - Emirati Arabi Uniti 4
LU - Lussemburgo 4
PL - Polonia 4
SC - Seychelles 4
AU - Australia 3
CM - Camerun 3
DK - Danimarca 3
MD - Moldavia 3
TW - Taiwan 3
CH - Svizzera 2
HR - Croazia 2
JP - Giappone 2
KH - Cambogia 2
MA - Marocco 2
NO - Norvegia 2
PK - Pakistan 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SM - San Marino 2
AL - Albania 1
BN - Brunei Darussalam 1
BR - Brasile 1
BZ - Belize 1
CO - Colombia 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
HU - Ungheria 1
KZ - Kazakistan 1
MX - Messico 1
NZ - Nuova Zelanda 1
Totale 17.211
Città #
Chandler 1.645
Dublin 1.605
Jacksonville 758
Beijing 627
Ashburn 586
Nanjing 406
Izmir 404
Dearborn 382
Ann Arbor 346
Princeton 323
Parma 318
San Mateo 233
Shanghai 209
Wilmington 186
Shenyang 158
New York 155
Kunming 143
Nanchang 135
Toronto 121
Düsseldorf 114
Helsinki 107
Hebei 105
Jinan 102
Des Moines 87
Hefei 87
Jiaxing 78
Bremen 74
Boardman 73
Tianjin 72
Vienna 72
Seattle 63
Los Angeles 61
Brussels 55
Changsha 55
Woodbridge 54
Kocaeli 52
Hangzhou 43
Focsani 39
Pune 39
Norwalk 37
Grafing 29
Zhengzhou 28
Guangzhou 26
Houston 26
Milan 24
Fremont 21
Mestre 21
Ningbo 20
Augusta 18
Chengdu 17
Taizhou 17
Borås 16
Fairfield 16
Haikou 16
Lanzhou 15
Leawood 15
Rockville 15
Washington 15
Phoenix 14
Redmond 14
Fuzhou 13
Cambridge 12
London 12
Timisoara 12
Wuhan 12
Chongqing 11
Modena 11
Monmouth Junction 11
Taiyuan 11
Edinburgh 10
Palermo 10
Rome 10
Trezzano Sul Naviglio 10
Amsterdam 9
Jesi 9
Rho 9
Torino 8
Xian 8
Ahmedabad 7
Auburn Hills 7
Bologna 7
Ottawa 7
Singapore 7
Sofia 7
Central 6
Chicago 6
Madrid 6
Nerviano 6
Redwood City 6
Romainville 6
Savignano sul Rubicone 6
Southend 6
St Louis 6
Ardabil 5
Lagos 5
Montreal 5
Mumbai 5
Old Bridge 5
Philadelphia 5
Reggio Emilia 5
Totale 10.911
Nome #
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 111
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 97
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 97
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 96
Are the Myeloma bone microevironment cells tumoral or not? 94
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 93
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 92
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 91
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 89
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 89
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 89
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 89
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 89
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 87
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 84
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 84
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 84
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 83
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 83
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 83
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 82
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 81
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 81
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 79
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 79
Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking 77
Angiopoietins expression by human myeloma cells 77
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 77
Possible targets to treat myeloma-related osteoclastogenesis 77
Novel targets for the treatment of relapsing multiple myeloma 77
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 76
Oncolytic virotherapy and microenvironment in multiple myeloma 76
Analysis of lineage involvment in Philadelphia chromosome positive acute lymphoblastic leukaemia 75
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 75
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 74
Bisphosphonates inhibit IL-6 production by human osteoblast-like cells 74
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 74
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma 74
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation 73
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 73
Do human myeloma cells directly produce basic FGF? 73
Angiogenic switch in multiple myeloma patients 72
Angiogenic properties of human myeloma cells: role of angiopoietin system 72
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 72
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 72
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 72
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 72
The Proteasome and Myeloma-Associated Bone Disease 72
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 72
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 72
Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo 71
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 71
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 71
Functional consequences of low activity of transport system a for neutral amino acids in human bone marrow mesenchymal stem cells 71
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 71
Expression and role of chemokine receptor CXCR3 in multiple myeloma 70
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 70
Macrophage inflammatory protein (MIP)-3 alpha/CCL20 and its receptor CCR6 are overexpressed in the bone microenvironment and involved in osteoclast formation in multiple myeloma patients. 70
5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men. 70
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 70
Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML 70
A simplified sars-cov-2 pseudovirus neutralization assay 70
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 69
Angiopoietin-1 and myeloma-induced angiogenesis 69
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 69
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 69
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in Multiple Myeloma patients 69
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 69
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 69
Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes 68
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 68
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 68
Osteopontin is produced by human multiple myeloma cells 67
Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients 67
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment 66
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 66
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 66
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 66
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 65
GPNA inhibits the sodium-independent transport system l for neutral amino acids 65
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 65
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 65
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 65
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis 65
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 64
Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma 64
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 64
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 64
Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycemia in insulin-dependent diabetics. 64
Effects of hematin and Mössbauer gamma-radiation on human osteosarcoma cell lines 64
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 64
Beta-catenin depended and independent effects induced by myeloma cells in human and murine osteoblasts and osteoblast progenitors. 63
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 63
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 63
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 63
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 62
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 62
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 62
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 62
p29ING4 regulates the production of pro-angiogenic molecules by human myeloma cells in normoxic and hypoxic conditions being involved in myeloma-induced angiogenesis. 62
Totale 7.386
Categoria #
all - tutte 61.200
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.200


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019574 0 0 0 0 0 0 0 0 0 0 496 78
2019/20203.390 673 685 159 29 203 309 340 70 255 373 102 192
2020/20211.687 77 171 139 18 244 24 144 47 377 87 292 67
2021/20221.590 31 23 26 110 37 57 199 202 77 145 128 555
2022/20236.260 724 647 387 452 535 671 158 400 1.960 74 187 65
2023/20241.840 110 237 55 58 191 623 195 163 54 126 28 0
Totale 17.633